Baird Medical Investment Holdings Ltd
Baird Medical Investment Holdings Ltd is a U.S.-listed medical device company focused on minimally invasive ablation technologies for solid tumors. Its business centers on microwave ablation systems and related products used in clinical settings, with operations and corporate functions rooted in China and commercial activity reaching multiple international markets.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueEnergy-based devices used for minimally invasive tissue ablation in clinical procedures.
Procedure-related items sold alongside the main ablation platforms and used in treatment workflows.
Development-stage IRE-based and other ablation products intended to broaden the portfolio.
Next-generation robotic ablation solutions under development for image-guided procedures.
Products
Reported · share of revenue- Microwave Ablation Needles76.4 %
- Microwave Ablation Therapeutic Apparatus23.6 %
Source: 20-F/A FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Baird Medical sells primarily to hospitals, medical centers, and private practice groups that perform minimally invasive tumor and thyroid procedures. Its products are used by interventional physicians who need image-guided ablation tools for soft tissue treatment, especially in settings that value lower-invasiveness alternatives to surgery. The company also addresses institutional buyers that adopt new technologies through clinical evaluation and physician preference.
Buy MWA systems and related tools for interventional oncology and thyroid procedures.
Purchase ablation platforms for outpatient and specialty-care procedures.
Influence purchasing by selecting devices that fit clinical workflow and outcomes.
Adopt the technology to evaluate new procedures and support training.
Strategy
The company’s strategy is to expand commercialization of its microwave ablation platform in the United States while continuing to build its international footprint. It is also broadening the product set with IRE-based products and an AI-powered robotic ablation system, aiming to deepen physician adoption and create a fuller procedure ecosystem. Regulatory clearances and sales coverage expansion are central to that plan because medical device adoption depends on both approvals and clinical uptake.
The U.S. market can materially broaden adoption of the core MWA platform and raise credibility with physicians.
More device options can increase share of wallet and reduce dependence on a single technology.
Clearances are required to launch and scale new medical devices in target markets.
International sales can diversify demand and support longer-term platform adoption.
Geography
Baird Medical is headquartered in Guangzhou, China, but it is also marketed as a U.S.-focused commercial platform for its microwave ablation systems. The company describes sales across multiple continents, with the United States and China both central to its operating footprint and regulatory strategy. This geography exposes the business to both U.S. and Chinese healthcare purchasing cycles, regulatory approvals, and cross-border execution risk.
Risks
The company depends on successful regulatory approvals, physician adoption, and market access in both the United States and China. As a medical device business, it also faces product development risk, competitive technology risk, and the possibility that clinical or commercial uptake of new ablation platforms may be slower than planned. Cross-border operations add execution risk because reimbursement, compliance, and sales channels differ across markets.
- Regulatory clearance delaysImpact: HighLikelihood: Medium
New devices cannot scale commercially until the relevant health authorities clear them.
Exposure: New product pipeline
- U.S. market execution riskImpact: HighLikelihood: Medium
The company is still building sales coverage and physician adoption in the U.S.
Exposure: Microwave ablation commercialization
- China expansion riskImpact: HighLikelihood: Medium
The company explicitly identifies expansion in China as a key uncertainty.
Exposure: International sales
- Technology adoption riskImpact: MediumLikelihood: Medium
Physicians may adopt competing ablation or surgical alternatives if outcomes or workflows are better.
Exposure: Core MWA platform
- Development risk on new platformsImpact: MediumLikelihood: Medium
IRE-based and robotic systems require R&D success and validation before meaningful revenue contribution.
Exposure: R&D pipeline
Accounting
Judgemental itemsDevice shipments, approvals, and launch timing can create uneven reported revenue across periods.
Impact: Comparability across quarters
The company reports substantial share-based compensation in adjusted EBITDA reconciliation.
Impact: Affects profitability and adjusted metrics
Capitalized equipment and intangible assets flow through earnings over time.
Impact: Impacts operating income and EBITDA bridge
A change in auditor and mention of material weaknesses increases reporting scrutiny.
Impact: Confidence in reported numbers
Similar listed companies
Publicly listed companies with a comparable business focus.
iTonic Holdings Ltd
ITOC · Electromedical & Electrotherapeutic Apparatus
iTonic Holdings Ltd is a U.S.-listed healthcare solutions company organized around Beijing Feitian Zhaoye Technology Co., Ltd., its wholly owned operating subsidiary in Beijing, China.
Meihua International Medical Technologies Co., Ltd.
MHUAF · Surgical & Medical Instruments & Apparatus
IceCure Medical Ltd.
ICCM · Surgical & Medical Instruments & Apparatus
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Pulse Biosciences, Inc
PLSE · Surgical & Medical Instruments & Apparatus
Pulse Biosciences is a U.S.-based medical technology company focused on developing and commercializing nonthermal pulsed field ablation systems.
InMode Ltd.
INMD · Electromedical & Electrotherapeutic Apparatus
Last updated: 28/09/2026